Objective To explore the clinical effect of two kinds of second-line treatment regimens for elderly diffuse large B-cell lymphoma (DLBCL). Methods A total of 96 elderly patients with DLBCL who were admitted to our hospital from July 2010 to July 2018 were selected as the subjects. The clinical data of the patients were retrospectively analyzed. Patients treated with R-ICE were included in control group (n=48), while those treated with R-GEMOX were included in observation group (n=48). The treatment effects were compared between the two groups. Results The response rate of the observation group was slightly higher than that of the control group (97.92% vs.93.75%)(P>0.05). The positive expression rates of FOXP1 and Livin in both groups decreased after treatment, and the positive expression rates of FOXP1 and Livin in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (10.42% vs.27.08%)(P<0.05). Conclusion The curative effect of R-GEMOX is better than R-ICE in the treatment of DLBCL. The former can significantly reduce the positive expression rates of FOXP1 and Livin and the incidence of adverse reactions.
International Medicine & Health Guidance News